Last reviewed · How we verify
NCT05173961
A Mobile Application, Oncpatient, to Assist Patients Undergoing Radiation Therapy
NA trial testing Internet-Based Intervention in Hematopoietic and Lymphoid Cell Neoplasm in 20 participants. Participants enrolled and being followed up; not accepting new ones.
15 June 2026
Quick facts
| Lead sponsor | City of Hope Medical Center |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 20 |
| Start date | 29 June 2022 |
| Primary completion | 15 June 2026 |
| Estimated completion | 15 June 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Internet-Based Intervention
- Survey Administration
Conditions studied
- Hematopoietic and Lymphoid Cell Neoplasm — all drugs for Hematopoietic and Lymphoid Cell Neoplasm →
- Malignant Solid Neoplasm — all drugs for Malignant Solid Neoplasm →
Sponsor
City of Hope Medical Center
Who can join
18 and older, any sex, with Hematopoietic and Lymphoid Cell Neoplasm or Malignant Solid Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial determines how well the oncpatient mobile application work in assisting patients undergoing radiation treatment. Radiation therapy can be complex. The technology, daily treatments, and possible side effects can be confusing to prevent and manage. Traditional radiation patient education includes a large amount of information, including details of treatment logistics, side effect prevention, and management. However, this information is not always readily accessible or memorable through the long course of therapy, and critical details can be missed. Oncpatient is a mobile application intended to be a more convenient and accessible form of patient education and guidance that is readily available to help patients and their caretakers navigate through radiation treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05173961
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Internet-Based Intervention
Trials testing the same drug.
- NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
- NCT05874297 — Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancer · NA · not yet recruiting
- NCT07302230 — Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Amon · NA · recruiting
- NCT07439484 — Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesoph · NA · not yet recruiting
- NCT07202247 — Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabol · Phase 2 · recruiting
Other recruiting trials for Hematopoietic and Lymphoid Cell Neoplasm
Currently open trials in the same condition.
- NCT05711667 — A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patien · Phase 3 · recruiting
- NCT06184321 — Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion · EARLY_PHASE1 · recruiting
- NCT06089408 — Weighted Blanket Use to Reduce Anxiety in Oncology Patients · NA · recruiting
- NCT05663502 — Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers · recruiting
- NCT05178472 — Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria) · NA · recruiting
Other City of Hope Medical Center trials
Trials by the same sponsor.
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
- NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
- NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
- NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05173961 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
- Last refreshed: 5 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05173961.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing